Heather N Tinsley

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7684462/heather-n-tinsley-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24 papers	1,025 citations	16 h-index	32 g-index
33 ext. papers	1,218 ext. citations	4.4 avg, IF	3.82 L-index

#	Paper	IF	Citations
24	Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. *Bioorganic Chemistry*, **2020**, 104, 104322	5.1	3
23	Cyclic GMP signaling during human lactation and breast cancer: Implications for breast cancer prevention. *Breast Journal*, **2019**, 25, 775-777	1.2	1
22	Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors. *Archiv Der Pharmazie*, **2016**, 349, 104-11	4.3	6
21	Ripped from the Headlines: Using Current Events and Deliberative Democracy to Improve Student Performance in and Perceptions of Nonmajors Biology Courses. *Journal of Microbiology and Biology Education*, **2016**, 17, 380-388	1.3	3
20	cGMP signaling as a target for the prevention and treatment of breast cancer. *Seminars in Cancer Biology*, **2015**, 31, 106-10	12.7	17
19	The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. *Cancers*, **2014**, 6, 436-58	6.6	132
18	New NSAID targets and derivatives for colorectal cancer chemoprevention. *Recent Results in Cancer Research*, **2013**, 191, 105-20	1.5	21
17	Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. *Molecular Cancer Therapeutics*, **2013**, 12, 1848-59	6.1	83
16	Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives. *European Journal of Medicinal Chemistry*, **2012**, 57, 329-43	6.8	14
15	Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases. *Current Colorectal Cancer Reports*, **2012**, 8, 325-330	1	6
14	A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. *Cancer Prevention Research*, **2012**, 5, 822-33	3.2	56
13	Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. *Journal of Medicinal Chemistry*, **2011**, 54, 495-509	8.3	39
12	Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. *Antioxidants and Redox Signaling*, **2011**, 15, 447-59	8.4	69
11	Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. *Cancer Prevention Research*, **2011**, 4, 1275-84	3.2	77
10	NSAIDs: Old Drugs Reveal New Anticancer Targets. *Pharmaceuticals*, **2010**, 3, 1652-1667	5.2	35
9	Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. *Cancer Prevention Research*, **2010**, 3, 1303-13	3.2	62
8	A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors. *Medicinal Chemistry*, **2010**, 6, 374-87	1.8	5

7	Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach. *European Journal of Medicinal Chemistry*, **2010**, 45, 90-7	6.8	50
6	Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. *European Journal of Medicinal Chemistry*, **2010**, 45, 1278-86	6.8	32
5	Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. *Arzneimittelforschung*, **2009**, 59, 415-21		7
4	A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. *Cancer Prevention Research*, **2009**, 2, 572-80	3.2	68
3	Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. *European Journal of Pharmacology*, **2009**, 602, 8-14	5.3	89
2	Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5974-82	3.4	66
1	Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. *Molecular Cancer Therapeutics*, **2009**, 8, 3331-40	6.1	82